Compare Merck & Co., Inc. (MRK) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Quantumscape Corp — how do they compare? Merck & Co., Inc. trades at $148.02 (market cap $366.28B), while Quantumscape Corp trades at $5.26 (market cap $3.44B). The key difference: Merck & Co., Inc. is far larger — about 106.5× Quantumscape Corp's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| MRK | QS | |
|---|---|---|
Market Cap | $366.28B | $3.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $18.44 |
52-Week Low | $77.60 | $4.89 |
Enterprise Value | $413.04B | $2.65B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
QuantumScape trades at $5.59, up 2.01% today but near 52-week lows, with a bearish technical signal from moving averages. The company is pre-revenue, reporting a net loss of $435.05M in 2025, negative ROE of -39.08%, and cash burn from operations. Recent news highlights insider sales and delayed commercialization timelines, with solid-state battery production not expected until 2029.
Outlook remains speculative with high execution risk; analyst consensus is cautious (0% buy, 73% hold, 27% sell). Investment hinges on successful battery commercialization by 2029, but competition and funding needs pose significant threats to shareholder value amid persistent losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
